A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

Pease, Christopher; Hutton, Brian; Yazdi, Fatemeh; Wolfe, Dianna; Hamel, Candyce; Barbeau, Pauline; Skidmore, Becky; Alvarez, Gonzalo G.

doi:10.1002/pds.4423

Cited by 51 publications

(31 citation statements)

References 76 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an incarcerated population, 5/91 (5.5%) developed transient fever and chills (28). A recent systematic review of the adverse events associated with 3HP found that rates of adverse events of this regimen compared favourably to those of other LTBI treatments but with higher rates of flu-like reactions and less hepatotoxicity (32). A comparison of INH9 and 3HP is summarized in Table 1.…”

Section: Adverse Eventsmentioning

confidence: 99%

A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

Pease

Amaratunga

Alvarez

2017

Canada Communicable Disease Report

View full text Add to dashboard Cite

Despite recent success in reducing its incidence, tuberculosis remains a considerable challenge in Canada, particularly among foreign-born and Indigenous populations. A key component of the strategy for controlling the disease is the treatment of latent tuberculosis infection (LTBI). The standard treatment consists of isoniazid (INH) daily for nine months. In recent years, shorter regimens have been developed in the hope of increasing rates of treatment acceptance and completion. Of these, the shortest and most recently developed is a combination of INH and rifapentine taken once weekly for 12 doses (3HP), typically using directly observed therapy. This regimen has been approved by the Food and Drug Administration in the United States but is not yet authorized for use in Canada.Based on a rapidly expanding number of observational studies and randomized controlled trials, 12 weeks of 3HP appears to have similar efficacy to nine months of INH, a favourable adverse event profile and potentially improved rates of treatment completion. Although rates of treatment acceptance, the role of self-administered therapy and the regimen's cost-effectiveness within the Canadian context remain uncertain, 3HP is a promising alternative to existing treatments for LTBI.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

Pease

Amaratunga

Alvarez

2017

Canada Communicable Disease Report

View full text Add to dashboard Cite

show abstract

“…These findings were also replicated in a large paediatric cohort nested within the larger trial [11]. The efficacy and safety of this new regimen have been established with phase 3 [10-12], phase 4 clinical trials [13,14] and observational studies [14][15][16][17][18] in addition to a network meta-analysis on efficacy and completion rates [19] and a systematic review of rifapentine adverse events compared to other treatments [20] done by our group.…”

Section: Introductionmentioning

confidence: 60%

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

Alvarez

Dyk

Mallick

et al. 2020

International Journal of Circumpolar Health

Self Cite

View full text Add to dashboard Cite

Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational postmarketing study was conducted introducing 3HP for the first time in Canada in Iqaluit followed by a program rollout in Qikiqtarjuaq, Nunavut. Results: A total of 247 people were offered 3HP, 102 in the Iqaluit postmarketing study and 145 in the Qikiqtarjuaq program roll out. Although statistical significance was not reached, more people who started treatment completed treatment in the 3HP group (Iqaluit, 60/73 (82.2%) and Qikiqtarjuaq, 89/115 (77.4%)) than in the historical control 9INHgroup (306/420 = 72.9%) (p = 0.2). Most of the adverse events in 3HP treated patients were associated with mild discomfort but no disruption of normal daily activity. Not drinking alcohol was associated with increased 3HP completion (OR 13.33, 95% CI, 2.27-78.20) as was not taking concomitant medications (OR 7.19, 95% CI, 1.47-35.30). Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut.

show abstract

“…In comparison to the standard regimen therapy for LTBI and to 3-month isoniazid-rifapentine regimen, the latter exhibits a similar efficacy of isoniazid monotherapy for six or nine months, presenting a low frequency of adverse effects and a higher completion rate. (77,78,79) Pretomanid (PA-824) (Table II) is a bicyclic imidazole able to destroy both replicant and non-replicating bacilli through different mechanisms. According to the authors, the inhibition of mycolic acids leads to cell wall disruption (isoniazid-like), which is the death-inducing effect of PA-824 against replicating/active bacteria, while its anaerobic killing activity is related to its NO releasing potential, causing respiratory poisoning in the microorganism.…”

Section: Tuberculosis Chemotherapymentioning

confidence: 99%

Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs

Araújo

Santos

Sanches

et al. 2020

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Malaria and tuberculosis are no longer considered to be neglected diseases by the World Health Organization. However, both are huge challenges and public health problems in the world, which affect poor people, today referred to as neglected populations. In addition, malaria and tuberculosis present the same difficulties regarding the treatment, such as toxicity and the microbial resistance. The increase of Plasmodium resistance to the available drugs along with the insurgence of multidrug-and particularly tuberculosis drug-resistant strains are enough to justify efforts towards the development of novel medicines for both diseases. This literature review provides an overview of the state of the art of antimalarial and antituberculosis chemotherapies, emphasising novel drugs introduced in the pharmaceutical market and the advances in research of new candidates for these diseases, and including some aspects of their mechanism/sites of action.

show abstract

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection

Cited by 51 publications

References 76 publications

A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs

Contact Info

Product

Resources

About